智通财经APP获悉，福森药业(01652)盘中涨近74%，截至发稿，涨49.28%，报1.03港元，成交额1037.15万港元。
消息面上，福森药业公告，集团的全资附属公司嘉亨(珠海横琴)医药科技有限公司研发的“恩扎卢胺软胶囊”，上市申请已获得中华人民共和国国家药品监督管理局批准，批准用于以下疾病的治疗：有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者；雄激素剥夺治疗(ADT)失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌(CRPC)成年患者。
福森药业同时公布，旗下产品二甲双胍恩格列净片(I)(盐酸二甲双胍500mg和恩格列净5mg)，于日前公布的中国第十一批全国药品集中采购招标结果中拟中标。据悉，福森药业今年9月公布，集团研发的“二甲双胍恩格列净片(I)”，上市申请已获得中国国家药品监督管理局批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.